Novartis buys Takeda ' s eye med Xiidra for $3.4 billion

The drugs is the only prescription treatment approved by the FDA for both signs and symptoms of dry eye disease, with a mechanism of action that targets inflammation

Source: PharmaManufacturing.com - July 2, 2019 Category: Pharmaceuticals Source Type: news